Freenome, Inc. (FRNM) · Oct 20, 2026 · Other events
SimpleScreen Lung launch — 85% sensitivity, 50% specificity, 99.8% NPV
Freenome’s lung cancer test is now available as an LDT, adding a one-draw CRC combo—but regulatory clearance and commercial uptake remain ahead.
Freenome is moving from a newly commercialized CRC test into a broader blood-based cancer-screening portfolio: SimpleScreen CRC received FDA approval in July 2026 and is being commercialized in the U.S. by Abbott, while SimpleScreen Lung had already received FDA Breakthrough Device designation in August. This filing turns that pipeline direction into an actual lung-test launch. Freenome says SimpleScreen Lung can be ordered alone or alongside SimpleScreen CRC, creating a practical two-cancer screening workflow from one blood draw. 〔0〕
The validation supports the product story, but does not yet establish a regulatory or commercial win. In an independent cohort of 172 lung-cancer cases and 436 controls, the test delivered 85% sensitivity, 50% specificity and a 99.8% negative predictive value. 〔1〕 The low 50% specificity means half of people without lung cancer could test positive and require follow-up, while the study is materially smaller and less definitive than the more than 48,000-participant prospective CRC study underpinning the existing product. 〔2〕
The key limitation is that SimpleScreen Lung is launching before FDA clearance. The company explicitly says the test is a laboratory-developed test and “has not been reviewed or cleared/approved by the U.S. Food and Drug Administration (FDA).” 〔3〕 That makes this a commercial-access and adoption step—not yet the regulatory validation that would broaden the addressable market or remove questions around clinical use.
The one-draw combination strengthens Freenome’s portfolio strategy, but execution is now the test. The offering is directionally consistent with the company’s previously disclosed Personalized Cancer Detection strategy and the expected expansion beyond CRC, so the surprise is the launch and the accompanying performance details rather than the concept itself. Freenome now has to demonstrate that providers will add an unapproved lung LDT to visits already used for CRC screening, while Abbott handles standalone CRC commercialization.
Bottom line: This advances Freenome from a one-product CRC story toward a multi-cancer screening platform, making it a meaningful operational step. The signal is modestly positive, but the lung product remains an early commercial experiment pending regulatory progress and real-world adoption.
Q3 2026 results, November 10
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!